Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies

Journal of Thrombosis and Haemostasis

Volumn 15, Issue 2, 2017, Pages 312-322

  Scully, M ^a   Cataland, S ^b   Coppo, P ^c   de la Rubia, J ^d   Friedman, K D ^e   Kremer Hovinga, J ^f   Lammle B ^g   Matsumoto, M ^h   Pavenski, K ⁱ   Sadler, E ^j   Sarode, R ^k   Wu, H ^b   Gale, D ^l   Fujimura, Y ^l   McDonald, V ^l   Peyvandi, F ^l   Scharrer, I ^l   Veyradier, A ^l   Westwood, J P ^l  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c HÔPITAL SAINT ANTOINE   (France)

^d HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

^g UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^h NARA MEDICAL UNIVERSITY   (Japan)

ⁱ ST MICHAEL'S HOSPITAL   (Canada)

^j WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^l NONE

more..

Author keywords

ADAMTS 13 protein, human; diagnosis, differential; thrombocytopenia; thrombotic microangiopathy; thrombotic thrombocytopenic purpura

Indexed keywords

BLEOMYCIN; COBALAMIN; GEMCITABINE; INTERFERON; MITOMYCIN; QUININE; SIMVASTATIN; TICLOPIDINE; TRIMETHOPRIM; VASCULOTROPIN INHIBITOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAMTS13 PROTEIN, HUMAN; COMPLEMENT; FIBRIN; VON WILLEBRAND FACTOR;

ARTICLE; CLINICAL FEATURE; CONNECTIVE TISSUE DISEASE; CONSENSUS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; HELLP SYNDROME; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALIGNANT NEOPLASM; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NOMENCLATURE; PANCREATITIS; PATIENT MONITORING; PREECLAMPSIA; PROGNOSIS; PUBLICATION; RELAPSE; REMISSION; STANDARDIZATION; STREPTOCOCCUS PNEUMONIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; ADULT; BLOOD; CHEMISTRY; CHILD; ERYTHROCYTE; FEMALE; HEMATOLOGY; HEMOLYSIS; INFLAMMATION; MEDICAL SOCIETY; METABOLISM; PLATELET COUNT; PREGNANCY; RECURRENT DISEASE; STANDARDS; THROMBOCYTE; THROMBOCYTE AGGREGATION; TREATMENT OUTCOME;

ADAMTS13 PROTEIN; ADULT; BLOOD PLATELETS; CHILD; COMPLEMENT SYSTEM PROTEINS; CONSENSUS; DIAGNOSIS, DIFFERENTIAL; ERYTHROCYTES; FEMALE; FIBRIN; HEMATOLOGY; HEMOLYSIS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; INFLAMMATION; PLATELET AGGREGATION; PLATELET COUNT; PREGNANCY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RECURRENCE; REMISSION INDUCTION; SOCIETIES, MEDICAL; TERMINOLOGY AS TOPIC; THROMBOTIC MICROANGIOPATHIES; TREATMENT OUTCOME; VON WILLEBRAND FACTOR;

EID: 85011711363     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13571     Document Type: Article

References (75)

1. Sarode R, Bandarenko N, Brecher ME, Kiss JE, Marques MB, Szczepiorkowski ZM, Winters JL. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29: 148–67.
2. Furlan M, Robles R, Solenthaler M, Wassmer M, Sandoz P, Lammle B. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura. Blood 1997; 89: 3097–103.
3. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585–94.
4. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost 2013; 39: 559–66.
5. Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Jozsi M. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles. Mol Immunol 2009; 46: 2801–7.
6. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH. The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 2013; 15: R12.
7. Keeler E, Fioravanti G, Samuel B, Longo S. Scleroderma renal crisis or thrombotic thrombocytopenic purpura: seeing through the masquerade. Lab Med 2015; 46: e39–44.
8. Turner RC, Chaplinski TJ, Adams HG. Rocky Mountain spotted fever presenting as thrombotic thrombocytopenic purpura. Am J Med 1986; 81: 153–7.
9. Morton JM, George JN. Microangiopathic hemolytic anemia and thrombocytopenia in patients with cancer. J Oncol Pract 2016; 12: 523–30.
10. Scully M, Hunt BJ, Benjamin S, Liesner R, Rose P, Peyvandi F, Cheung B, Machin SJ, British Committee for Standards in Haematology. Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies. Br J Haematol 2012; 158: 323–35.
11. Coppo P, Wolf M, Veyradier A, Bussel A, Malot S, Millot GA, Daubin C, Bordessoule D, Pene F, Mira JP, Heshmati F, Maury E, Guidet B, Boulanger E, Galicier L, Parquet N, Vernant JP, Rondeau E, Azoulay E, Schlemmer B. Reseau d'Etude des Microangiopathies Thrombotiques de lA. Prognostic value of inhibitory anti-ADAMTS-13 antibodies in adult-acquired thrombotic thrombocytopenic purpura. Br J Haematol 2006; 132: 66–74.
12. Loirat C, Veyradier A, Girma JP, Ribba AS, Meyer D. Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS-13) deficiency in children. Semin Thromb Hemost 2006; 32: 90–7.
13. Veyradier A, Obert B, Haddad E, Cloarec S, Nivet H, Foulard M, Lesure F, Delattre P, Lakhdari M, Meyer D, Girma JP, Loirat C. Severe deficiency of the specific von Willebrand factor-cleaving protease (ADAMTS-13) activity in a subgroup of children with atypical hemolytic uremic syndrome. J Pediatr 2003; 142: 310–17.
14. Wu N, Liu J, Yang S, Kellett ET, Cataland SR, Li H, Wu HM. Diagnostic and prognostic values of ADAMTS-13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura. Transfusion (Paris) 2015; 55: 18–24.
15. Jin M, Casper TC, Cataland SR, Kennedy MS, Lin S, Li YJ, Wu HM. Relationship between ADAMTS-13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651–8.
16. Westwood JP, Webster H, McGuckin S, McDonald V, Machin SJ, Scully M. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost 2013; 11: 481–90.
17. Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007; 136: 451–61.
18. Hie M, Gay J, Galicier L, Provot F, Presne C, Poullin P, Bonmarchand G, Wynckel A, Benhamou Y, Vanhille P, Servais A, Bordessoule D, Coindre JP, Hamidou M, Vernant JP, Veyradier A, Coppo P. Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood 2014; 124: 204–10.
19. Lotta LA, Garagiola I, Palla R, Cairo A, Peyvandi F. ADAMTS-13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura. Hum Mutat 2010; 31: 11–19.
20. Kokame K, Matsumoto M, Soejima K, Yagi H, Ishizashi H, Funato M, Tamai H, Konno M, Kamide K, Kawano Y, Miyata T, Fujimura Y. Mutations and common polymorphisms in ADAMTS-13 gene responsible for von Willebrand factor-cleaving protease activity. Proc Natl Acad Sci USA 2002; 99: 11902–7.
21. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001; 413: 488–94.
22. Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T. Natural history of Upshaw–Schulman syndrome based on ADAMTS-13 gene analysis in Japan. J Thromb Haemost 2011; 9(Suppl. 1): 283–301.
23. Scully M, Starke R, Lee R, Mackie I, Machin S, Cohen H. Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. Blood Coagul Fibrinolysis 2006; 17: 459–63.
24. Moatti-Cohen M, Garrec C, Wolf M, Boisseau P, Galicier L, Azoulay E, Stepanian A, Delmas Y, Rondeau E, Bezieau S, Coppo P, Veyradier A. Unexpected frequency of Upshaw–Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood 2012; 119: 5888–97.
25. von Krogh AS, Kremer Hovinga JA, Tjonnfjord GE, Ringen IM, Lammle B, Waage A, Quist-Paulsen P. The impact of congenital thrombotic thrombocytopenic purpura on pregnancy complications. Thromb Haemost 2014; 111: 1180–3.
26. Furlan M, Robles R, Morselli B, Sandoz P, Lammle B. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999; 81: 8–13.
27. Scully M, Brown J, Patel R, McDonald V, Brown CJ, Machin S. Human leukocyte antigen association in idiopathic thrombotic thrombocytopenic purpura: evidence for an immunogenetic link. J Thromb Haemost 2010; 8: 257–62.
28. Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, Hunt B, Benjamin S, Patel R, Machin S, Scully M. Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol 2011; 153: 515–19.
29. McCarthy LJ, Porcu P, Fausel CA, Sweeney CJ, Danielson CF. Thrombotic thrombocytopenic purpura and simvastatin. Lancet 1998; 352: 1284–5.
30. Thomas MR, McDonald V, Machin SJ, Scully MA. Thrombotic thrombocytopenic purpura associated with statin therapy. Blood Coagul Fibrinolysis 2011; 22: 762–3.
31. Martin MG, Whitlatch NL, Shah B, Arepally GM. Thrombotic thrombocytopenic purpura induced by trimethoprim-sulfamethoxazole in a Jehovah's Witness. Am J Hematol 2007; 82: 679–81.
32. Sallee M, Cretel E, Jean R, Chiche L, Bourliere M, Poullin P, Lefevre P, Durand JM. Thrombotic thrombocytopenic purpura complicating interferon therapy in chronic C hepatitis. Gastroenterol Clin Biol 2008; 32: 145–6.
33. Roriz M, Landais M, Desprez J, Barbet C, Azoulay E, Galicier L, Wynckel A, Baudel JL, Provot F, Pene F, Mira JP, Presne C, Poullin P, Delmas Y, Kanouni T, Seguin A, Mousson C, Servais A, Bordessoule D, Perez P, et al. Risk factors for autoimmune diseases development after thrombotic thrombocytopenic purpura. Medicine (Baltimore) 2015; 94: 1–8.
34. Schattner A, Friedman J, Klepfish A. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol 2002; 21: 57–9.
35. Malak S, Wolf M, Millot GA, Mariotte E, Veyradier A, Meynard JL, Korach JM, Malot S, Bussel A, Azoulay E, Boulanger E, Galicier L, Devaux E, Eschwege V, Gallien S, Adrie C, Schlemmer B, Rondeau E, Coppo P. Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS-13 activity. Scand J Immunol 2008; 68: 337–44.
36. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, Deuschl G, Fellermann K, Fickenscher H, Gerigk C, Goettsche A, Greeve J, Hafer C, Hagenmuller F, Haller H, Herget-Rosenthal S, et al. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345: 1–13.
37. Vieira-Martins P, El Sissy C, Bordereau P, Gruber A, Rosain J, Fremeaux-Bacchi V. Defining the genetics of thrombotic microangiopathies. Transfus Apher Sci 2016; 54: 212–19.
38. Dragon-Durey MA, Blanc C, Garnier A, Hofer J, Sethi SK, Zimmerhackl LB. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin Thromb Hemost 2010; 36: 633–40.
39. Lemaire M, Fremeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, Ji W, Overton JD, Mane SM, Nurnberg G, Altmuller J, Thiele H, Morin D, Deschenes G, Baudouin V, Llanas B, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45: 531–6.
40. Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D, Valoti E, Remuzzi G, Noris M. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol 2013; 24: 475–86.
41. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169–81.
42. Nishimura J, Yamamoto M, Hayashi S, Ohyashiki K, Ando K, Brodsky AL, Noji H, Kitamura K, Eto T, Takahashi T, Masuko M, Matsumoto T, Wano Y, Shichishima T, Shibayama H, Hase M, Li L, Johnson K, Lazarowski A, Tamburini P, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med 2014; 370: 632–9.
43. Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009; 24: 687–96.
44. Miyakawa Y, Imada K, Ichinohe T, Nishio K, Abe T, Murata M, Ueda Y, Fujimura Y, Matsumoto M, Okamoto S. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol 2016; 104: 228–35.
45. Toussaint-Hacquard M, Coppo P, Soudant M, Chevreux L, Mathieu-Nafissi S, Lecompte T, Gross S, Guillemin F, Schneider T. Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study. Transfusion (Paris) 2015; 55: 2445–51.
46. Scully M, McDonald V, Cavenagh J, Hunt BJ, Longair I, Cohen H, Machin SJ. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood 2011; 118: 1746–53.
47. Peyvandi F, Lavoretano S, Palla R, Feys HB, Vanhoorelbeke K, Battaglioli T, Valsecchi C, Canciani MT, Fabris F, Zver S, Reti M, Mikovic D, Karimi M, Giuffrida G, Laurenti L, Mannucci PM. ADAMTS-13 and anti-ADAMTS-13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008; 93: 232–9.
48. Scully M, Thomas M, Underwood M, Watson H, Langley K, Camilleri RS, Clark A, Creagh D, Rayment R, McDonald V, Roy A, Evans G, McGuckin S, Ni Ainle F, Maclean R, Lester W, Nash M, Scott R, O'Brien P. Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes. Blood 2014; 124: 211–19.
49. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437–54.
50. Benhamou Y, Assie C, Boelle PY, Buffet M, Grillberger R, Malot S, Wynckel A, Presne C, Choukroun G, Poullin P, Provot F, Gruson D, Hamidou M, Bordessoule D, Pourrat J, Mira JP, Le Guern V, Pouteil-Noble C, Daubin C, Vanhille P, et al. Development and validation of a predictive model for death in acquired severe ADAMTS-13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Haematologica 2012; 97: 1181–6.
51. Hughes C, McEwan JR, Longair I, Hughes S, Cohen H, Machin S, Scully M. Cardiac involvement in acute thrombotic thrombocytopenic purpura: association with troponin T and IgG antibodies to ADAMTS-13. J Thromb Haemost 2009; 7: 529–36.
52. Cataland SR, Yang SB, Witkoff L, Kraut EH, Lin S, George JN, Wu HM. Demographic and ADAMTS-13 biomarker data as predictors of early recurrences of idiopathic thrombotic thrombocytopenic purpura. Eur J Haematol 2009; 83: 559–64.
53. Thomas MR, de Groot R, Scully MA, Crawley JT. Pathogenicity of anti-ADAMTS-13 autoantibodies in acquired thrombotic thrombocytopenic purpura. EBioMedicine 2015; 2: 940–50.
54. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS-13 assay. Br J Haematol 2005; 129: 93–100.
55. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS-13 activity. Transfusion (Paris) 2006; 46: 1444–52.
56. Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE. An optimized fluorogenic ADAMTS-13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1511–18.
57. Jin M, Cataland S, Bissell M, Wu HM. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost 2006; 4: 333–8.
58. Hubbard AR, Heath AB, Kremer Hovinga JA. Establishment of the WHO 1st International Standard ADAMTS-13, plasma (12/252): communication from the SSC of the ISTH. J Thromb Haemost 2015; 13: 1151–3.
59. Peyvandi F, Palla R, Lotta LA, Mackie I, Scully MA, Machin SJ. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631–40.
60. Meyer SC, Sulzer I, Lammle B, Kremer Hovinga JA. Hyperbilirubinemia interferes with ADAMTS-13 activity measurement by FRETS-VWF73 assay: diagnostic relevance in patients suffering from acute thrombotic microangiopathies. J Thromb Haemost 2007; 5: 866–7.
61. Studt JD, Kremer Hovinga JA, Antoine G, Hermann M, Rieger M, Scheiflinger F, et al. Fatal congenital thrombotic thrombocytopenic purpura with apparent ADAMTS13 inhibitor: in vitro inhibition of ADAMTS13 activity by hemoglobin. Blood 2005; 105: 542–4.
62. Mackie I, Langley K, Chitolie A, Liesner R, Scully M, Machin S, Peyvandi F. Discrepancies between ADAMTS-13 activity assays in patients with thrombotic microangiopathies. Thromb Haemost 2013; 109: 488–96.
63. Spinale JM, Ruebner RL, Kaplan BS, Copelovitch L. Update on Streptococcus pneumoniae associated hemolytic uremic syndrome. Curr Opin Pediatr 2013; 25: 203–8.
64. Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol 2007; 22: 2097–103.
65. Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lammle B, Moake JL, Richardson P, Socie G, Zeigler Z, Niederwieser D, Barbui T. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica 2007; 92: 95–100.
66. Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM. Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Biol Blood Marrow Transplant 2014; 20: 518–25.
67. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145: 24–33.
68. Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med 2011; 8: e1001013.
69. Martin JN Jr, Rinehart BK, May WL, Magann EF, Terrone DA, Blake PG. The spectrum of severe preeclampsia: comparative analysis by HELLP (hemolysis, elevated liver enzyme levels, and low platelet count) syndrome classification. Am J Obstet Gynecol 1999; 180: 1373–84.
70. Zakarija A, Kwaan HC, Moake JL, Bandarenko N, Pandey DK, McKoy JM, Yarnold PR, Raisch DW, Winters JL, Raife TJ, Cursio JF, Luu TH, Richey EA, Fisher MJ, Ortel TL, Tallman MS, Zheng XL, Matsumoto M, Fujimura Y, Bennett CL. Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989–2008). Kidney Int Suppl. 2009; 112: S20–4.
71. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: frequency, clinical features, and long-term outcomes. Ann Intern Med 2001; 135: 1047–51.
72. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129–36.
73. McDonald V, Laffan M, Benjamin S, Bevan D, Machin S, Scully MA. Thrombotic thrombocytopenic purpura precipitated by acute pancreatitis: a report of seven cases from a regional UK TTP registry. Br J Haematol 2009; 144: 430–3.
74. Swisher KK, Doan JT, Vesely SK, Kwaan HC, Kim B, Lammle B, Kremer Hovinga JA, George JN. Pancreatitis preceding acute episodes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: report of five patients with a systematic review of published reports. Haematologica 2007; 92: 936–43.
75. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore) 2012; 91: 195–205.